The development of Alzheimer’s vaccines has been another biotech highlight of 2023.
The development of Alzheimer’s vaccines has been another biotech highlight of 2023. American company Vaxxinity’s UB-311, a notable candidate, targets toxic forms of amyloid beta in the brain. In phase 2 trials, UB-311 demonstrated safety and triggered an immune response, suggesting a new pathway for Alzheimer’s treatment. This synthetic, peptide-based active immunotherapy is part of Vaxxinity’s innovative Vaxxine Platform, which aims to create peptides that induce a target-specific antibody response. The potential of such vaccines is immense, offering a more affordable and longer-lasting alternative to current treatments.